1. Home
  2. PBYI vs BGX Comparison

PBYI vs BGX Comparison

Compare PBYI & BGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Puma Biotechnology Inc

PBYI

Puma Biotechnology Inc

N/A

Current Price

$5.88

Market Cap

263.4M

Sector

Health Care

ML Signal

N/A

Logo Blackstone Long Short Credit Income Fund

BGX

Blackstone Long Short Credit Income Fund

N/A

Current Price

$10.70

Market Cap

139.7M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
PBYI
BGX
Founded
2010
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
263.4M
139.7M
IPO Year
2011
2010

Fundamental Metrics

Financial Performance
Metric
PBYI
BGX
Price
$5.88
$10.70
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$7.00
N/A
AVG Volume (30 Days)
467.8K
137.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.61
N/A
Revenue
$27,685,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$9.84
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.58
$10.38
52 Week High
$7.68
$12.65

Technical Indicators

Market Signals
Indicator
PBYI
BGX
Relative Strength Index (RSI) 40.44 30.09
Support Level $5.57 N/A
Resistance Level $7.25 $11.89
Average True Range (ATR) 0.43 0.14
MACD -0.11 -0.00
Stochastic Oscillator 17.89 47.06

Price Performance

Historical Comparison
PBYI
BGX

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

About BGX Blackstone Long Short Credit Income Fund

Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It seeks to achieve its investment objectives by employing a dynamic long-short strategies in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.

Share on Social Networks: